ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
39.38
0.74%
US Tech 100
20,836.00
1.31%
S&P 500
5,930.85
1.09%
US Dollar vs CAD
1.43421
0.00%
Bitcoin
97,017.92
-0.19%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Cardiol Therapeutics Inc (CRDL)

  7. Cardiol Therapeutics Inc (CRDL) News

Cardiol Therapeutics Inc

Cardiol Therapeutics Inc (CRDL)

Cordel Group Plc
Cardiol Therapeutics Inc
1.28
-0.03
(-2.29%)
Closed December 22 3:00PM
Delayed by 15 minutes
1.28
-0.005
(-0.39%)
After Hours: 6:22PM
Delayed by 15 minutes

Professional-Grade Tools, for Individual Investors.

Premium

CRDL News

Official News Only

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
November 18 2024
CRDL (-2.29%)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
November 14 2024
CRDL (-2.29%)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
October 22 2024
CRDL (-2.29%)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
October 11 2024
CRDL (-2.29%)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
October 10 2024
CRDL (-2.29%)

Form SUPPL - Voluntary Supplemental Material by Foreign Issuers [Section 11(a)]
Edgar (US Regulatory)
October 09 2024
CRDL (-2.29%)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
October 09 2024
CRDL (-2.29%)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
October 08 2024
CRDL (-2.29%)

Form SUPPL - Voluntary Supplemental Material by Foreign Issuers [Section 11(a)]
Edgar (US Regulatory)
October 08 2024
CRDL (-2.29%)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
September 24 2024
CRDL (-2.29%)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
September 10 2024
CRDL (-2.29%)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
August 12 2024
CRDL (-2.29%)

Form EFFECT - Notice of Effectiveness
Edgar (US Regulatory)
July 16 2024
CRDL (-2.29%)

CRDL Discussion

View Posts
Monksdream Monksdream 17 hours ago
CRDL, under $2
👍️0
MahinAgency MahinAgency 4 weeks ago
NASDAQ: $CRDL SHORT SQUEEZE ALERTS

Financial Strategy: With about $21 million in cash, the company may consider a small capital raise if new data boosts the stock price, aiming for a target of $10 per share (C$13.60
👍️0
MahinAgency MahinAgency 4 weeks ago
NASDAQ: $CRDL

Cardiol Therapeutics MAvERIC-Pilot Study Results:

Safety: High tolerability and 95% compliance.

Next Steps: Data supports advancing to Phase II/III MAVERIC-2 and Phase III MAVERIC-3 trials
👍️0
MahinAgency MahinAgency 4 weeks ago
A target of $10 per share (approximately C$13.60) is proposed, indicating a potential upside of over 5x within a year, contingent on strong data readouts for CardiolRx™?
👍️0
MahinAgency MahinAgency 4 weeks ago
NASDAQ: $CRDL

Advancement: Results support Phase II/III MAVERIC-2 and Phase III MAVERIC-3 trials, expanding accessibility to non-immunosuppressive oral therapy.

Short Squeeze Alerts $CRDL, BIG OPPORTUNITY
👍️0
MahinAgency MahinAgency 4 weeks ago
NASDAQ: $CRDL

Cardiol Therapeutics sets a 12-month price target of $10, valuing CardiolRx at $9 for recurrent pericarditis and $1 for acute myocarditis, based on projected sales and associated probabilities.
👍️0
MahinAgency MahinAgency 4 weeks ago
NASDAQ: $CRDL Pick Up This Morning Short Sueeze Aler

 MAvERIC-Pilot Results:
Safety: High tolerance, 95% compliance.
Next Steps: Advancing to Phase II/III MAVERIC-2 and Phase III MAVERIC-3 trials
👍️0
MahinAgency MahinAgency 1 month ago
NASDAQ: $CRDL MAvERIC-Pilot Study:

Efficacy: Significant reductions in pericarditis pain (mean score 5.8 to 1.5) and inflammation (CRP normalized in 80% of patients). Episodes dropped from 5.8/year to 0.9 during the trial.

👍️0
MahinAgency MahinAgency 1 month ago
Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024
👍️0
MahinAgency MahinAgency 1 month ago
INSIDER BUYING : Cardiol CEO David Elsley purchased approximately $100,000 in shares at about $2.03 each, indicating strong personal conviction in the company's potential.
👍️0
MahinAgency MahinAgency 1 month ago
$CRDL Here are the MAvERIC-Pilot study results that we’ve been waiting for! 

❤️Marked and rapid reductions in both pericarditis pain and inflammation  maintained throughout the 26-week study!

❤️Episodes of pericarditis per year substantially reduced 

❤️MAvERIC-Pilot results support advancing CardiolRx™ into the Phase II/III MAVERIC-2
and the Phase III MAVERIC-3 clinical trials

Congratulations to all long term shareholders! 
👍️0
MahinAgency MahinAgency 1 month ago
NASDAQ: $CRDL BIG NEWS:

Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024
👍️0
MahinAgency MahinAgency 1 month ago
Breaking News: NASDAQ: $CRDL unveils groundbreaking results for CardiolRx™ at the American Heart Association Conference! 📷 Rapid pain relief, 85% fewer recurrences, and lasting inflammation reduction.
👍️0
MahinAgency MahinAgency 1 month ago
NASDAQ: $CRDL 12-Month Price Target: $10 based on a sum-of-the-parts valuation.

Valued at $9 per share, assuming $609M in sales

Valued at $1 per share, assuming $132M in sales
👍️0
MahinAgency MahinAgency 1 month ago
NASDAQ: $CRDL RED TO GREEN, Looks Good

Cardiol Therapeutics Inc Today at 11:15am EST Dr. Allen Luis MayoClinic will present the Pericarditis full clinical data at #AHA2024
👍️0
MahinAgency MahinAgency 1 month ago
NASDAQ: $CRDL SHORT SQUEEZE ALERTS, STAY TUNED

Addressing urgent unmet medical needs: CardiolRx™ targets acute myocarditis, a life-threatening condition with no FDA-approved treatments
👍️0
MahinAgency MahinAgency 1 month ago
NASDAQ: $CRDL 12-Month Price Target: $10 based on a sum-of-the-parts valuation.

 Valued at $9 per share, assuming $609M in sales by 2033

Valued at $1 per share, assuming $132M in sales by 2033
👍 1
MahinAgency MahinAgency 1 month ago
NASDAQ: $CRDL The 12-month price target is $10, with $9 attributed to recurrent pericarditis and $1 to acute myocarditis

Recently raised $13.5 million to fund developments?, SHORT SQUEEZE ALERTS
👍️0
MahinAgency MahinAgency 1 month ago
NASDAQ: $CRDL lets See Red To Green, 

H.C. Wainwright maintains a "Buy" rating for Cardiol Therapeutics with a price target of $9.00.

The company recently raised $13.5 million
👍️0
MahinAgency MahinAgency 1 month ago
NASDAQ: $CRDL The company recently raised $13.5 million, ensuring financial backing for ongoing clinical developments and corporate growth
👍️0
MahinAgency MahinAgency 1 month ago
Picked up NASDAQ: $CRDL this morning…low float runner on news incoming… Short Squeeze Alerts

The 12-month price target is $10, with $9 attributed to recurrent pericarditis and $1 to acute myocarditis
👍️0
tw0122 tw0122 1 month ago
30 million shares offering at .26 October 30th
👍️0
MahinAgency MahinAgency 1 month ago
H.C. Wainwright maintains a "Buy" rating for Cardiol Therapeutics with a price target of $9.00.

MAVERIC-2 trial aims to assess CardiolRx in recurrent pericarditis patients post-IL-1 blocker therapy.
👍️0
MahinAgency MahinAgency 1 month ago
$CRDL up over 220% year-to-date; analysts raised the price target from $4.50 to $11.00, keeping a "Speculative Buy" rating.
👍️0
MahinAgency MahinAgency 1 month ago
NASDAQ: $CRDL SHORT SQUEEZE ALERTS

H.C. Wainwright maintains a "Buy" rating for Cardiol Therapeutics with a price target of $9.00.

MAVERIC-2 trial aims to assess CardiolRx in recurrent pericarditis patients post-IL-1 blocker therapy.
👍️0
MahinAgency MahinAgency 1 month ago
NASDAQ: $CRDL Financial Strategy: With about $21 million in cash, the company may consider a small capital raise if new data boosts the stock price,aiming for a target of $10 per share (C$13.60
👍️0
MahinAgency MahinAgency 1 month ago
Key Points:

Rating & Price Target: H.C. Wainwright maintains a "Buy" rating for Cardiol Therapeutics (CRDL) with a price target of $9.00.
New Trial: MAVERIC-2 trial aims to assess CardiolRx in recurrent pericarditis (RP) patients post-IL-1 blocker therapy.
Market Advantage: CardiolRx could serve as an earlier treatment alternative, competing with Arcalyst, which costs $300,000 annually.
Strategic Expansion: By targeting unmet needs in the RP market, CardiolRx is positioned to broaden its market potential.
👍️0
MahinAgency MahinAgency 1 month ago
NASDAQ: $CRDL up over 220% year-to-date; analysts raised the price target from $4.50 to $11.00, keeping a "Speculative Buy" rating.

Recently raised $13.5 million to fund developments?
👍️0
MahinAgency MahinAgency 1 month ago
Big coming Next week 💃💃💃💃
👍️0
MahinAgency MahinAgency 1 month ago
NASDAQ: $CRDL
ARCHER trial completed enrollment, with results expected in Q1 2025. Orphan status could lead to $120M peak sales 

Promising early results, potential approval by 2027, targeting $609M peak sales

👍️0
MahinAgency MahinAgency 1 month ago
NASDAQ: $CRDL With about $21 million in cash, the company may consider a small capital raise if new data boosts the stock price, aiming for a target of $10 per share (C$13.60

$CRDL BIG SHORT SQUEEZE 
👍️0
tw0122 tw0122 1 month ago
Chart looking good $2.07 next targets $4
👍️0
glenn1919 glenn1919 1 month ago
CRDL........................https://stockcharts.com/h-sc/ui?s=CRDL&p=W&b=5&g=0&id=p86431144783
👍️0
MahinAgency MahinAgency 1 month ago
NASDAQ: $CRDL sets a 12-month price target of $10, valuing CardiolRx at $9 for recurrent pericarditis and $1 for acute myocarditis, based on projected sales and associated probabilities.
👍️0
MahinAgency MahinAgency 1 month ago
NASDAQ: $CRDL up over 220% year-to-date; analysts raised the price target from $4.50 to $11.00, keeping a "Speculative Buy" rating.

👍️0
MahinAgency MahinAgency 1 month ago
NASDAQ: $CRDL 12-Month Price Target: $10 based on a sum-of-the-parts valuation.

Cardiol had around $21 million in cash at the end of Q1 


👍️0
MahinAgency MahinAgency 1 month ago
NASDAQ: $CRDL
 Cardiol Therapeutics recently reported encouraging outcomes from its Phase II MAvERIC trial of CardiolRx, an ultra-pure oral cannabidiol formulation for recurrent pericarditis.

The 12-month price target is $10
👍️0
MahinAgency MahinAgency 2 months ago
NASDAQ: $CRDL Cardiol Therapeutics sets a 12-month price target of $10, valuing CardiolRx at $9 for recurrent pericarditis and $1 for acute myocarditis, based on projected sales and associated probabilities.
👍️0
MahinAgency MahinAgency 2 months ago
NASDAQ: CRDL is advancing CardiolRx™ for acute myocarditis and recurrent pericarditis, both in Phase II trials. The company raised $13.5 million
👍️0
MahinAgency MahinAgency 2 months ago
NASDAQ: $CRDL CEO Investment: Cardiol CEO David Elsley purchased approximately $100,000 in shares at about $2.03 each, indicating strong personal conviction in the company's potential.
👍️0
MahinAgency MahinAgency 2 months ago
NASDAQ: $CRDL With about $21 million in cash, the company may consider a small capital raise if new data boosts the stock price, aiming for a target of $10 per share (C$13.60
👍️0
MahinAgency MahinAgency 2 months ago
NASDAQ: $CRDL is advancing CardiolRx™ for acute myocarditis and recurrent pericarditis, both in Phase II trials. The company raised $13.5 million

👍️0
MahinAgency MahinAgency 2 months ago
NASDAQ: $CRDL A target of $10 per share (approximately C$13.60) is proposed, indicating a potential upside of over 5x within a year, contingent on strong data readouts for CardiolRx™?
👍️0
MahinAgency MahinAgency 2 months ago
Cardiol Therapeutics sets a 12-month price target of $10, valuing CardiolRx at $9 for recurrent pericarditis and $1 for acute myocarditis, based on projected sales and associated probabilities.
👍️0
MahinAgency MahinAgency 2 months ago
$CRDL Insider Buying: Cardiol CEO David Elsley purchased approximately $100,000 in shares at about $2.03 each
👍️0
MahinAgency MahinAgency 2 months ago
NASDAQ: $CRDL Cardiol Therapeutics sets a 12-month price target of $10, valuing CardiolRx at $9 for recurrent pericarditis and $1 for acute myocarditis, based on projected sales and associated probabilities
👍️0
MahinAgency MahinAgency 2 months ago
NASDAQ: $CRDL 12-month price target is $10, with $9 attributed to recurrent pericarditis and $1 to acute myocarditis

👍️0
MahinAgency MahinAgency 2 months ago
NASDAQ: $CRDL is advancing CardiolRx for acute myocarditis and recurrent pericarditis, both in Phase II trials. The company raised $13.5 million

Cardiol sets a 12-month price target of $10
👍️0
MahinAgency MahinAgency 2 months ago
NASDAQ: $CRDL Short Squeeze Allerts 

A target of $10 per share (approximately C$13.60) is proposed, indicating a potential upside of over 5x within a year, contingent on strong data readouts for CardiolRx™?
👍️0
MahinAgency MahinAgency 2 months ago
Volume looks GOOD 💃💃🚀
👍️0

Your Recent History

NASDAQ
CRDL
Cardiol Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads